MeSH D009471 - neuromyelitis optica
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Satralizumab | Enspryng | 2021-06-24 | $289.64 M | Q4/22-Q3/23 | |
| Horizon Therapeutics Public | Inebilizumab | Uplizna | 2020-06-11 | |||
| Genentech | Satralizumab | Enspryng | 2020-08-14 |
Clinical Trials
Historical Success Rate
Phase 1
76%13/17
Phase 2
56%14/25
Phase 3
50%10/20
Approved: 4Overall Success rate: 21%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use